通过Dostarlimab诱导的免疫媒介糖尿病:一个病例报告
Andreia Pataco1, Bruna Pimentel2, Margarida Lagarto3
1Endocrinology and Nutrition Department. Hospital Divino Espírito Santo de Ponta Delgada. Ponta Delgada. Portugal.
免疫检查点抑制剂 (ICI) 很少引起免疫媒介糖尿病. 这一案例突出显示了PD-1抑制剂delarlimab的首例,在患有子宫内膜癌的患者中诱导糖尿病,强调早期检测和管理.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
背景情况:
- 针对PD-1/PD-L1的免疫检查点抑制剂 (ICI) 在癌症治疗中至关重要.
- 已知与ICI相关的免疫媒介不良事件,但糖尿病很罕见.
- 多斯塔利马布是一种用于治疗子宫内膜癌的PD-1抑制剂.
研究的目的:
- 报告第一个免疫媒介糖尿病的病例,这种病例是由 dostarlimab.
- 突出这一罕见不良事件的临床表现和管理.
主要方法:
- 一个78岁的女性患有子宫内膜腺癌的病例报告.
- 管理六个周期的 dostarlimab.
- 对糖尿病酸性,HbA1c,C-和自身免疫抗体的临床评估.
主要成果:
- 患者在提供利利马布治疗后发展出糖尿病酸性酸症.
- 自身免疫抗体是负的,但临床表现表明ICI诱导的糖尿病.
- 停止服用达拉利马布导致腹腔疾病的解决.
结论:
- 多斯塔利马布可以诱导免疫媒介糖尿病,这是一个罕见但显著的不良事件.
- 早期识别和管理对于接受duralimab的患者至关重要.
- 这一案例强调了用ICI监测内分泌毒性的重要性.
更多相关视频
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Dipeptidyl Peptidase 4 Inhibitors
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
